ArticleFrontiers in oncology2026

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis.

Anthony S Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.